DiaMedica Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

DiaMedica Therapeutics

15/05/2023 23:47

* DiaMedica Therapeutics Inc  DMAC.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended in
March. The mean expectation of three analysts for the quarter
was for a loss of 16 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * DiaMedica Therapeutics Inc's reported EPS for the quarter
was a
loss of 20 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * DiaMedica Therapeutics Inc shares had risen by 5.9% this
quarter and gained 2.5% so far this year.
    * The company reported a quarterly loss of $5.27 million.
    * Wall Street's median 12-month price target for DiaMedica
Therapeutics Inc is $7.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 10:47 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.16          -0.20          Missed
 Dec. 31 2022      -0.14          -0.14          Met
 Sep. 30 2022      -0.15          -0.12          Beat
 Jun. 30 2022      -0.18          -0.13          Beat